These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 19286392)
1. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Olsen T; Goll R; Cui G; Christiansen I; Florholmen J Cytokine; 2009 May; 46(2):222-7. PubMed ID: 19286392 [TBL] [Abstract][Full Text] [Related]
2. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187 [TBL] [Abstract][Full Text] [Related]
3. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Olsen T; Cui G; Goll R; Husebekk A; Florholmen J Scand J Gastroenterol; 2009; 44(6):727-35. PubMed ID: 19294580 [TBL] [Abstract][Full Text] [Related]
4. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757 [TBL] [Abstract][Full Text] [Related]
5. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis. Moriconi F; Raddatz D; Ho NA; Yeruva S; Dudas J; Ramadori G Transl Res; 2007 Oct; 150(4):223-32. PubMed ID: 17900510 [TBL] [Abstract][Full Text] [Related]
6. A review of infliximab use in ulcerative colitis. Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261 [TBL] [Abstract][Full Text] [Related]
7. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis. Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117 [TBL] [Abstract][Full Text] [Related]
8. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Olsen T; Goll R; Cui G; Husebekk A; Vonen B; Birketvedt GS; Florholmen J Scand J Gastroenterol; 2007 Nov; 42(11):1312-20. PubMed ID: 17852866 [TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Hassan C; Ierardi E; Burattini O; De Francesco V; Zullo A; Stoppino G; Panella C; Morini S Dig Liver Dis; 2007 Sep; 39(9):811-7. PubMed ID: 17652038 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Su C; Salzberg BA; Lewis JD; Deren JJ; Kornbluth A; Katzka DA; Stein RB; Adler DR; Lichtenstein GR Am J Gastroenterol; 2002 Oct; 97(10):2577-84. PubMed ID: 12385442 [TBL] [Abstract][Full Text] [Related]
11. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. Masuda H; Iwai S; Tanaka T; Hayakawa S J Clin Lab Immunol; 1995; 46(3):111-23. PubMed ID: 8926619 [TBL] [Abstract][Full Text] [Related]
12. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Steenholdt C; Molazahi A; Ainsworth MA; Brynskov J; Østergaard Thomsen O; Seidelin JB Scand J Gastroenterol; 2012 May; 47(5):518-27. PubMed ID: 22375898 [TBL] [Abstract][Full Text] [Related]
13. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Rahimi R; Nikfar S; Abdollahi M Med Sci Monit; 2007 Jul; 13(7):PI13-8. PubMed ID: 17599035 [TBL] [Abstract][Full Text] [Related]
14. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis. Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924 [TBL] [Abstract][Full Text] [Related]
15. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm. Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779 [TBL] [Abstract][Full Text] [Related]
16. Infliximab in the treatment of steroid-dependent ulcerative colitis. Armuzzi A; De Pascalis B; Lupascu A; Fedeli P; Leo D; Mentella MC; Vincenti F; Melina D; Gasbarrini G; Pola P; Gasbarrini A Eur Rev Med Pharmacol Sci; 2004; 8(5):231-3. PubMed ID: 15638236 [TBL] [Abstract][Full Text] [Related]
17. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis. Fratila OC; Craciun C J Gastrointestin Liver Dis; 2010 Jun; 19(2):147-53. PubMed ID: 20593047 [TBL] [Abstract][Full Text] [Related]
18. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Turner D; Griffiths AM; Veerman G; Johanns J; Damaraju L; Blank M; Hyams J Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1460-5. PubMed ID: 23672831 [TBL] [Abstract][Full Text] [Related]
19. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Watson KD; Silman AJ; Symmons DP; Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046 [TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice. Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]